Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) price on Thursday, March 20, fall -37.65% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.28.
A look at the stock’s price movement, the close in the last trading session was $0.45, moving within a range at $0.2642 and $0.43. The beta value (5-Year monthly) was 2.511. Turning to its 52-week performance, $1.65 and $0.44 were the 52-week high and 52-week low respectively. Overall, ADAP moved -51.60% over the past month.
Adaptimmune Therapeutics Plc ADR’s market cap currently stands at around $71.65 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-12.
The average forecast suggests up to a 3,576.95% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 183.3M, representing a 204.07% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ADAP is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 4 recommend ADAP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ADAP’s current price about -42.46% and -49.05% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 15.79, while 7-day volatility ratio is 17.88% and 11.35% in the 30-day chart. Further, Adaptimmune Therapeutics Plc ADR (ADAP) has a beta value of 2.61, and an average true range (ATR) of 0.05. Analysts have given the company’s stock an average 52-week price target of $3, forecast between a low of $1 and high of $4. Looking at the price targets, the low is -257.14% off current price level while to achieve the yearly target high, price needs to move -1328.57%. Nonetheless, investors will most likely welcome a -971.43% jump to $3 which is the analysts’ median price.
If we refocus on Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP), historical trading data shows that trading volumes averaged 2.41 over the past 10 days and 1.36 million over the past 3 months. The company’s latest data on shares outstanding shows there are 255.70 million shares.
The 11.49% of Adaptimmune Therapeutics Plc ADR’s shares are in the hands of company insiders while institutional holders own 37.31% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.36 million on 2025-02-28, giving us a short ratio of 7.43. The data shows that as of 2025-02-28 short interest in Adaptimmune Therapeutics Plc ADR (ADAP) stood at 373.0 of shares outstanding, with shares short falling to 6.88 million registered in 2025-01-31. Current price change has pushed the stock -48.02% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ADAP stock continues to rise going into the next quarter.
